The Hygiology Post is presenting information about a company that seems to have much potential to help many people. Both 2012 and 2013 appear to be pivotal years in determining how helpful the patented technologies may actually be for people.
Senesco Technologies has continued to update information on its web site (https://www.senesco.com/; obtained on 01-16-13). As a matter of disclosure : The author continues to be a current shareholder in the company.
An article in “Seeking Alpha” titled “Investing In The Future Of Multiple Myeloma Treatment” (https://seekingalpha.com/article/1114001-investing-in-the-future-of-multiple-myeloma-treatment?source=yahoo; obtained on 1-16-13) that was apparently published just hours ago (2:31 AM EST per “Headlines” on Yahoo Finance) and apparently written by Brian Wilson was not on Senesco Technologies web site. The article does seem to present an interesting perspective on several companies including Senesco Technologies. Here is an excerpt :
“…SNS01-T – leading the attack on a new potential oncogene, Senesco Technologies (SNT)
Senesco is an undiscovered name that caught my attention for two big reasons. One was the fact that Harlan Waksal was chairman of the board at the company (he is famous for creating ImClone – now a subsidy of Eli Lilly), as well as Christopher Forbes (of the Forbes family). CEO Dr. Leslie Brown also has a great track record.
The second was the fact that the company was brand new – at least in the sense that it only became a biopharmaceutical company a few years ago (2009). On top of that, the company had a very unique angle for the treatment of multiple myeloma. The eIF5A gene affects proteins that are integral to the process of apoptosis (programmed cell death). Malignant cells can replicate infinitely because of the destruction of the apoptosis pathway, which is made by nature to destroy cells that have “flaws” (like every cancer does). I think that eIF5A could be an extremely interesting target for all cancer types, although I don’t think multiple myeloma was a bad first choice. Note that Senesco also intends to expand SNS01-T’s indication to mantle cell lymphoma and other B-cell malignancies, along with myeloma.”
Louis DeCola, Jr. © 2013 The Hygiology Post ®